Of critical importance, piceatannol and tyrphostin 23-mediated toxicity appears significantly limited on wild-type organoids and mouse models, rendering both metabolic activators promising clinical targets against LKB1-deficient tumours. The gene discussed is STK11; the disease is neoplasm.